Precigen Inc (PGEN)

$1.42

+0.02

(+1.43%)▲

Market is closed - opens 7 PM, 25 Apr 2024

Insights on Precigen Inc

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 16.72M → 1.22M (in $), with an average decrease of 92.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 87.37M → -33.05M (in $), with an average decrease of 137.8% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 49.7% return, outperforming this stock by 24.0%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 240.7% return, outperforming this stock by 323.1%

Performance

  • $1.39
    $1.43
    $1.42
    downward going graph

    2.11%

    Downside

    Day's Volatility :2.8%

    Upside

    0.7%

    downward going graph
  • $0.84
    $1.88
    $1.42
    downward going graph

    41.17%

    Downside

    52 Weeks Volatility :55.56%

    Upside

    24.47%

    downward going graph

Returns

PeriodPrecigen IncSector (Health Care)Index (Russel 2000)
3 Months
0.0%
1.7%
0.0%
6 Months
31.48%
11.3%
0.0%
1 Year
25.66%
5.4%
1.3%
3 Years
-82.73%
13.9%
-22.1%

Highlights

Market Capitalization
348.5M
Book Value
$0.48
Earnings Per Share (EPS)
-0.39
Wall Street Target Price
9.0
Profit Margin
0.0%
Operating Margin TTM
-1904.64%
Return On Assets TTM
-30.29%
Return On Equity TTM
-78.37%
Revenue TTM
6.2M
Revenue Per Share TTM
0.03
Quarterly Revenue Growth YOY
-30.3%
Gross Profit TTM
20.6M
EBITDA
-82.3M
Diluted Eps TTM
-0.39
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.34
EPS Estimate Next Year
-0.27
EPS Estimate Current Quarter
-0.08
EPS Estimate Next Quarter
-0.07

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Precigen Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
9
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 533.8%

Current $1.42
Target $9.00

Company Financials

FY18Y/Y Change
Revenue
160.6M
↓ 30.48%
Net Income
-509.3M
↑ 335.26%
Net Profit Margin
-317.2%
↓ 266.54%
FY19Y/Y Change
Revenue
90.7M
↓ 43.5%
Net Income
-207.8M
↓ 59.21%
Net Profit Margin
-229.0%
↑ 88.2%
FY20Y/Y Change
Revenue
103.2M
↑ 13.73%
Net Income
-103.8M
↓ 50.05%
Net Profit Margin
-100.58%
↑ 128.42%
FY21Y/Y Change
Revenue
103.9M
↑ 0.67%
Net Income
-96.8M
↓ 6.75%
Net Profit Margin
-93.16%
↑ 7.42%
FY22Y/Y Change
Revenue
26.9M
↓ 74.09%
Net Income
-79.8M
↓ 17.56%
Net Profit Margin
-296.47%
↓ 203.31%
FY23Y/Y Change
Revenue
6.2M
↓ 76.87%
Net Income
-95.9M
↑ 20.22%
Net Profit Margin
-1.5K%
↓ 1244.16%
Q3 FY22Q/Q Change
Revenue
16.7M
↑ 474.44%
Net Income
-7.6M
↓ 70.67%
Net Profit Margin
-45.71%
↑ 849.48%
Q4 FY22Q/Q Change
Revenue
1.8M
↓ 89.46%
Net Income
-22.2M
↑ 190.11%
Net Profit Margin
-1.3K%
↓ 1212.15%
Q1 FY23Q/Q Change
Revenue
1.9M
↑ 4.99%
Net Income
-22.7M
↑ 2.52%
Net Profit Margin
-1.2K%
↑ 29.66%
Q2 FY23Q/Q Change
Revenue
1.8M
↓ 4.54%
Net Income
-20.3M
↓ 10.62%
Net Profit Margin
-1.1K%
↑ 78.28%
Q3 FY23Q/Q Change
Revenue
16.7M
↑ 846.35%
Net Income
87.4M
↓ 530.04%
Net Profit Margin
522.54%
↑ 1672.46%
Q4 FY23Q/Q Change
Revenue
1.2M
↓ 92.66%
Net Income
-33.1M
↓ 137.83%
Net Profit Margin
-2.7K%
↓ 3214.4%
FY18Y/Y Change
Total Assets
716.2M
↓ 15.43%
Total Liabilities
337.5M
↑ 12.37%
FY19Y/Y Change
Total Assets
455.8M
↓ 36.36%
Total Liabilities
384.1M
↑ 13.81%
FY20Y/Y Change
Total Assets
314.6M
↓ 30.98%
Total Liabilities
247.4M
↓ 35.58%
FY21Y/Y Change
Total Assets
359.9M
↑ 14.39%
Total Liabilities
252.5M
↑ 2.06%
FY22Y/Y Change
Total Assets
216.0M
↓ 39.98%
Total Liabilities
89.7M
↓ 64.47%
FY23Y/Y Change
Total Assets
151.0M
↓ 30.07%
Total Liabilities
41.6M
↓ 53.58%
Q3 FY22Q/Q Change
Total Assets
259.2M
↓ 19.29%
Total Liabilities
116.7M
↓ 56.05%
Q4 FY22Q/Q Change
Total Assets
216.0M
↓ 16.69%
Total Liabilities
89.7M
↓ 23.13%
Q1 FY23Q/Q Change
Total Assets
241.5M
↑ 11.84%
Total Liabilities
57.4M
↓ 36.01%
Q2 FY23Q/Q Change
Total Assets
207.5M
↓ 14.08%
Total Liabilities
41.3M
↓ 28.04%
Q3 FY23Q/Q Change
Total Assets
190.7M
↓ 8.11%
Total Liabilities
43.0M
↑ 4.1%
Q4 FY23Q/Q Change
Total Assets
151.0M
↓ 20.79%
Total Liabilities
41.6M
↓ 3.18%
FY18Y/Y Change
Operating Cash Flow
-124.2M
↑ 19.3%
Investing Cash Flow
-151.2M
↓ 244.93%
Financing Cash Flow
309.8M
↑ 7131.44%
FY19Y/Y Change
Operating Cash Flow
-135.9M
↑ 9.41%
Investing Cash Flow
86.9M
↓ 157.44%
Financing Cash Flow
8.1M
↓ 97.37%
FY20Y/Y Change
Operating Cash Flow
-77.0M
↓ 43.34%
Investing Cash Flow
27.8M
↓ 68.02%
Financing Cash Flow
32.7M
↑ 301.88%
FY21Y/Y Change
Operating Cash Flow
-55.8M
↓ 27.59%
Investing Cash Flow
-74.5M
↓ 368.33%
Financing Cash Flow
121.2M
↑ 270.55%
FY22Y/Y Change
Operating Cash Flow
-65.0M
↑ 16.63%
Investing Cash Flow
226.4M
↓ 403.75%
Financing Cash Flow
-155.3M
↓ 228.14%
Q3 FY22Q/Q Change
Operating Cash Flow
-23.8M
↑ 237.63%
Investing Cash Flow
11.4M
↓ 31.09%
Financing Cash Flow
-115.7M
↑ 102319.47%
Q4 FY22Q/Q Change
Operating Cash Flow
-15.4M
↓ 35.35%
Investing Cash Flow
11.4M
↑ 0.0%
Financing Cash Flow
-39.3M
↓ 66.06%
Q1 FY23Q/Q Change
Operating Cash Flow
-18.4M
↑ 19.43%
Investing Cash Flow
-50.4M
↓ 541.36%
Financing Cash Flow
44.2M
↓ 212.45%
Q2 FY23Q/Q Change
Operating Cash Flow
-15.8M
↓ 14.25%
Investing Cash Flow
23.5M
↓ 146.63%
Financing Cash Flow
-14.6M
↓ 133.02%

Technicals Summary

Sell

Neutral

Buy

Precigen Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Precigen Inc
Precigen Inc
1.07%
31.48%
25.66%
-82.73%
-67.65%
Moderna, Inc.
Moderna, Inc.
-1.39%
41.81%
-19.31%
-38.71%
322.88%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-5.68%
13.74%
14.81%
80.88%
159.02%
Novo Nordisk A/s
Novo Nordisk A/s
-2.24%
29.49%
49.67%
240.51%
421.0%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-3.67%
10.39%
20.74%
84.71%
129.52%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Precigen Inc
Precigen Inc
NA
NA
NA
-0.34
-0.78
-0.3
NA
0.48
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-6.77
-0.29
-0.12
NA
36.27
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
26.13
26.13
1.46
45.02
0.16
0.08
NA
242.47
Novo Nordisk A/s
Novo Nordisk A/s
48.36
48.36
2.4
3.34
0.88
0.23
0.01
23.9
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
29.17
29.17
0.53
16.75
0.23
0.13
NA
68.22
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Precigen Inc
Precigen Inc
Buy
$348.5M
-67.65%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$41.3B
322.88%
24.73
-68.84%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$99.6B
159.02%
26.13
30.14%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$573.9B
421.0%
48.36
36.03%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$104.7B
129.52%
29.17
36.68%

Institutional Holdings

  • Patient Capital Management, LLC

    6.42%

  • BlackRock Inc

    4.47%

  • Vanguard Group Inc

    2.71%

  • Geode Capital Management, LLC

    1.21%

  • Millennium Management LLC

    1.14%

  • State Street Corporation

    1.08%

Corporate Announcements

  • Precigen Inc Earnings

    Precigen Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

precigen, inc. discovers and develops the next generation of gene and cellular therapies in the united states. it also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; proprietary methane bioconversion platform that turns natural gas into energy and chemical products; and reproductive and embryo transfer technologies. in addition, the company offers ultravector platform that incorporates advanced dna construction technologies and computational models to design and assemble genetic components into complex gene expression programs; mbil15, a gene that enhances functional characteristics of immune cells; sleeping beauty, a non-viral transposon/transposase system; attsite recombinases, which breaks and rejoins dna at specific sequences; adenoverse technology platform, a library of engineered adenovector serotypes; and l. lactis is a food-grade bacterium. additionally, it provides rheoswitch inducible gene switch that provides qua

Organization
Precigen Inc
Employees
202
CEO
Mr. Randal J. Kirk J.D.
Industry
Health Technology

Discover More

FAQs